
Share Your Feedback or Recommend New Topics
ASF CEO, Amanda Moore sits down with researchers and clinicians who understand both the science and the lived experience of Angelman syndrome. They discuss what the ASPIRE results tell us, what they don’t tell us, and what researchers can learn from the trial. They discuss why the trial did not meet its primary or secondary endpoints, why the results of one clinical trial don't necessarily tell the whole story, and how researchers are working to better measure the changes that matter most to individuals and families.
Joining Amanda on the Podcast:
Wen-Hann Tan, MD, Clinical Geneticist and Head of the ASF Clinic at Boston Children’s Hospital
Anne Wheeler, PhD, Senior Research Public Health Analyst at RTI International and Licensed Psychologist at UNC’s Carolina Institute for Developmental Disabilities
Dan Harvey, PhD, Former Vice President, Operations, Alume Biosciences
Elizabeth Jalazo, MD, PPMH, Clinical Geneticist at UNC Chapel Hill, ASF Chief Medical Officer
Becky Burdine, PhD, Professor of Molecular Biology at Princeton University, Chair ASF Scientific Advisory Committee
See Q&A on the ASPIRE Trial Results and What they Mean for the Angelman Community here: https://bit.ly/4z5mWBM
Mais episódios de "Angelman Syndrome Foundation Podcast"



Não percas um episódio de “Angelman Syndrome Foundation Podcast” e subscrevê-lo na aplicação GetPodcast.








